Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ: IMCR )

30.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 30.40
Bid (Size) 12.16 (2)
Ask (Size) 36.61 (1)
Prev. Close 30.40
Today's Range 30.40 - 30.40
52wk Range 27.69 - 76.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire

Performance

YTD
+1.95%
+1.95%
1 Month
+5.15%
+5.15%
3 Month
-5.56%
-5.56%
6 Month
-22.98%
-22.98%
1 Year
-57.92%
-57.92%

More News

Read More
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
From Immunocore Holdings plc
Via GlobeNewswire
Navigating 8 Analyst Ratings For Immunocore Hldgs
Via Benzinga
A Closer Look at 9 Analyst Recommendations For Immunocore Hldgs
Via Benzinga
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
From Immunocore Holdings plc
Via GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Via Benzinga
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Analyst Ratings For Immunocore Hldgs
Via Benzinga
Analyst Expectations For Immunocore Hldgs's Future
Via Benzinga
3 Fast-Growing Stocks Analysts See Doubling in Price
Via MarketBeat
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
The Latest Analyst Ratings For Immunocore Hldgs
Via Benzinga
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the 2024 Cantor Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces transition of Chief Financial Officer
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights
Via Benzinga
3 Small-Cap Stocks with Significant Growth Potential
Via InvestorPlace
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
From Immunocore Holdings plc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.